HIL to commercialise VCRC Bti bio-larvicide technology for mosquito vector control programs
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
Strengthens investment in channels of the future to expand patient reach
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated